Stryker (NYSE:SYK) announced its quarterly earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.15 by $0.03, Bloomberg Earnings reports. The firm had revenue of $3.80 billion during the quarter, compared to the consensus estimate of $3.73 billion. Stryker had a return on equity of 27.60% and a net margin of 26.12%.
Shares of NYSE SYK opened at $185.29 on Thursday. Stryker has a twelve month low of $144.75 and a twelve month high of $186.17. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $68.34 billion, a PE ratio of 25.35, a PEG ratio of 2.25 and a beta of 0.86.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, March 28th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 1.12%. Stryker’s dividend payout ratio (DPR) is 28.45%.
Several equities research analysts recently weighed in on the company. Credit Suisse Group raised Stryker to an “outperform” rating in a report on Thursday, January 31st. Oppenheimer set a $170.00 price target on Stryker and gave the stock a “hold” rating in a report on Friday, November 9th. Citigroup decreased their price target on Stryker from $174.00 to $169.00 and set a “neutral” rating for the company in a report on Wednesday, January 2nd. Zacks Investment Research reiterated a “hold” rating and issued a $162.00 price objective on shares of Stryker in a research report on Monday, December 31st. Finally, UBS Group initiated coverage on Stryker in a research report on Tuesday, November 27th. They issued a “neutral” rating and a $180.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $185.37.
In related news, VP Bijoy Sagar sold 2,361 shares of the business’s stock in a transaction that occurred on Friday, December 7th. The stock was sold at an average price of $171.24, for a total transaction of $404,297.64. Following the completion of the transaction, the vice president now owns 2,361 shares in the company, valued at approximately $404,297.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Michael Damon Hutchinson sold 15,995 shares of the business’s stock in a transaction that occurred on Friday, February 8th. The shares were sold at an average price of $180.49, for a total value of $2,886,937.55. The disclosure for this sale can be found here. Insiders sold a total of 43,259 shares of company stock valued at $7,515,747 over the last quarter. Company insiders own 7.30% of the company’s stock.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Recommended Story: Tariff
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.